Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹150 Cr
down ₹7.3 Cr vs Apr 2014
- Stocks held
- 24
- unchanged
- Top 10 weight
- 79.6%
- of the portfolio in its ten largest
- Cash & debt
- 2.2%
- cash, money market and debt
- Moves this month
- 0 in · 0 out
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In May 2014 it disclosed 24 stocks worth ₹150 Cr, down ₹7.3 Cr from Apr 2014. Its largest positions were Sun Pharmaceutical Industries Limited (22.4%), Dr. Reddy's Laboratories Limited (16.1%), Lupin Limited (11.6%); the ten largest together made up 79.6% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 87.1% of its equity. Cash and debt stood at 2.2%. Compared with Apr 2014 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
97%
Top-10 weight is higher than 97% of peers
Breadth
7%
Holds more stocks than 7% of peers
Cash
30%
Holds more cash than 30% of peers
What these mean: concentration · cash
Holdings in May 2014
Download CSVEvery line the fund disclosed, with the change against Apr 2014. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 22.41% | up 0.26 pts | ₹33.7 Cr | down ₹1.2 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 16.13% | up 0.89 pts | ₹24.2 Cr | up ₹23 L | Added |
| Lupin Limited | 11.59% | up 2.38 pts | ₹17.4 Cr | up ₹2.9 Cr | Added |
| Cipla Limited | 8.98% | up 0.13 pts | ₹13.5 Cr | down ₹45 L | Trimmed |
| Divi's Laboratories Limited | 4.87% | down 0.16 pts | ₹7.3 Cr | down ₹61 L | Trimmed |
| Biocon Limited | 3.74% | down 0.10 pts | ₹5.6 Cr | down ₹43 L | Trimmed |
| Ranbaxy Laboratories Ltd | 3.51% | down 0.03 pts | ₹5.3 Cr | down ₹31 L | Trimmed |
| Zydus Lifesciences Limited | 2.94% | up <0.01 pts | ₹4.4 Cr | down ₹21 L | Trimmed |
| Aurobindo Pharma Limited | 2.84% | up 0.52 pts | ₹4.3 Cr | up ₹62 L | Added |
| Glenmark Pharmaceuticals Limited | 2.60% | down 0.11 pts | ₹3.9 Cr | down ₹37 L | Trimmed |
| Wyeth Ltd | 2.38% | up 0.16 pts | ₹3.6 Cr | up ₹7 L | Added |
| IPCA Laboratories Limited | 2.22% | down 0.02 pts | ₹3.3 Cr | down ₹20 L | Trimmed |
| Cash, TREPS & receivables | 2.17% | down 5.78 pts | ₹3.3 Cr | down ₹9.3 Cr | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 1.99% | up 0.07 pts | ₹3 Cr | down ₹4 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 1.82% | down 0.08 pts | ₹2.7 Cr | down ₹26 L | Trimmed |
| Strides Pharma Science Limited | 1.76% | up 0.02 pts | ₹2.7 Cr | down ₹9 L | Trimmed |
| Indoco Remedies Limited | 1.51% | up 0.34 pts | ₹2.3 Cr | up ₹42 L | Added |
| Sanofi India Limited | 1.33% | up 0.18 pts | ₹2 Cr | up ₹18 L | Added |
| Piramal Enterprises Limited | 1.18% | up 0.28 pts | ₹1.8 Cr | up ₹36 L | Added |
| Natco Pharma Limited | 1.00% | up 0.91 pts | ₹1.5 Cr | up ₹1.4 Cr | Added |
| Unichem Laboratories Limited | 0.98% | down 0.08 pts | ₹1.5 Cr | down ₹20 L | Trimmed |
| SHASUN PHARMACEUTICALS LTD. | 0.96% | up 0.17 pts | ₹1.4 Cr | up ₹20 L | Added |
| Torrent Pharmaceuticals Limited | 0.56% | up 0.05 pts | ₹84 L | up ₹5 L | Added |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.34% | up 0.01 pts | ₹52 L | down ₹1 L | Trimmed |
| Pfizer Limited | 0.18% | up <0.01 pts | ₹26 L | down ₹1 L | Trimmed |
What changed, Apr 2014 to May 2014
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Lupin Limitedup ₹2.9 Cr (+2.38% pts)
- Natco Pharma Limitedup ₹1.4 Cr (+0.91% pts)
- Aurobindo Pharma Limitedup ₹62 L (+0.52% pts)
- Indoco Remedies Limitedup ₹42 L (+0.34% pts)
- Piramal Enterprises Limitedup ₹36 L (+0.28% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Apr 2014, the weight rose most in Finance (+0.2 pts), and fell most in Pharmaceuticals & Biotechnology (−0.1 pts).
- Finance1.0% → 1.2%+0.2 pts
- Pharmaceuticals & Biotechnology87.2% → 87.1%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Feb 2014 | Apr 2014 | May 2014 |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 91.8% | 87.2% | 87.1% |
| Pharmaceuticals | 7.2% | 11.8% | 11.7% |
| Finance | 1.0% | 1.0% | 1.2% |
Allocation in May 2014change vs Apr 2014
- Pharmaceuticals & Biotechnology (16)87.1%▼ 0.1 pts
- Pharmaceuticals (7)11.7%▼ 0.1 pts
- Finance (1)1.2%▲ 0.2 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, May 2014
2.2%
▼ 5.8 pts vs Apr 2014
- Cash alone
- 2.2%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- 2.2% – 11.6%
- lowest to highest · record 11.6% in Mar 2014
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.